



ASX ANNOUNCEMENT

EXPIRY OF OPTIONS APPENDIX 3Y

SYDNEY, Wednesday, 12 June 2013: Cellmid Limited (ASX: CDY) advises that 2,000,000 Director Options have lapsed unexercised as at 16 April 2013. The delay in notification has been due to an administrative oversight by the Company.

The Company has a policy that requires Directors to obtain the approval of the Chairman or the Board before trading in the securities of the Company. As the lapsing of the Director Options required no action by the holder this change in interest was inadvertently overlooked.

Attached is an Appendix 3Y – Change of Director’s Interest Notice relating to the Director’s options that have lapsed.

End

Contact:
Maria Halasz, CEO
T +612 9221 6830

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases, heart attack and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company’s most advanced development programme is for the treatment of inflammatory disorders and cancer using its large portfolio of anti-midkine antibodies.

Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. Cellmid is commercialising midkine as a biomarker for cancer diagnosis. The first product with midkine as one of the markers, CxBladder, was launched in the US in early 2013.

In 2010 Cellmid set up a dedicated subsidiary, Advangen International Pty Ltd, for the development of midkine for hair growth. Through this subsidiary, the Company acquired exclusive rights in certain territories to a range of hair growth products utilising FGF-5 inhibition technology. The products have since been listed with the TGA and launched on the Australian pharmacy market. The Company intends to expand the distribution of these products internationally in the future.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Cellmid Limited
ABN	69 111 304 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ms Maria Halasz
Date of last notice	3 April 2013

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	A) Direct B) Indirect C) Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	A) Maria Halasz B) Direct Capital Pty Ltd – entity controlled by Director as Trustee for the Halasz Family Retirement Fund C) Direct Capital Group Pty Ltd – entity controlled by the Director
Date of change	B) 16 Apr 2013
No. of securities held prior to change	A) 1,050,000 fully paid ordinary shares B) 5,700,000 fully paid ordinary shares 2,000,000 unlisted opts exp 16 Apr 2013 ex price \$.05735 3,000,000 unlisted opts exp 3 Jul 2013 ex price \$.05735 7,000,000 unlisted opts exp 20 Nov 2014 ex price \$0.056 1,362,625 listed opts exp 23 Oct 2016 ex price \$0.034 C) 5,000,000 unlisted opts exp 15 June 2017 ex price \$0.032

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	B) Unlisted options
Number acquired	Nil
Number disposed	B) 2,000,000 unlisted options, expired
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	A) 1,050,000 fully paid ordinary shares B) 5,700,000 fully paid ordinary shares 3,000,000 unlisted opts exp 3 Jul 2013 ex price \$0.05735 7,000,000 unlisted opts exp 20 Nov 2014 ex price \$0.056 1,362,625 listed opts exp 23 Oct 2016 ex price \$0.034 C) 5,000,000 unlisted opts exp 15 June 2017 ex price \$0.032
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	B) Expiry of unlisted options

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	N/A in case of expiry of options
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

12 June 2013

⁺ See chapter 19 for defined terms.